Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial

Synchron announced this week that its Stentrode brain-computer interface has been successfully implanted in 100 patients across clinical sites in the United States, Australia, and the United Kingdom, marking a significant commercial and regulatory inflection point for the endovascular BCI company. The milestone positions Synchron as the first BCI developer to reach triple-digit human implants without requiring open-brain surgery, a distinction the company says has been central to accelerating physician adoption and patient enrollment.

The Stentrode device is delivered through the jugular vein and lodged in a blood vessel adjacent to the motor cortex, where it records neural signals that patients can use to control computers, communicate, and operate smart home devices. Unlike competing approaches that require craniotomy, the endovascular method carries a comparatively lower procedural risk profile, a factor regulators and hospital ethics boards have cited favorably during review processes.

Synchron CEO Tom Oxley confirmed in a briefing that the company plans to file for a pivotal trial with the U.S. Food and Drug Administration before the end of 2026, with the goal of supporting a de novo or PMA submission pathway for a commercially approved indication in patients with severe motor impairment caused by ALS, spinal cord injury, or stroke. Data from the existing cohort will form the safety and efficacy backbone of that filing.

The announcement arrives amid intensifying competition in the implantable BCI space. Neuralink continues expanding its PRIME study following its first human implant in early 2024, while Precision Neuroscience has been steadily growing its cortical electrode strip program. Analysts at Cowen estimate the addressable market for motor-assistive BCIs could reach $4.2 billion annually by 2032, driven primarily by ALS and spinal cord injury populations in high-income markets.

Investor interest remains strong. Synchron closed a $75 million Series D extension in March, bringing total funding to over $320 million. Backers include ARCH Venture Partners, Khosla Ventures, and strategic investor Microsoft, whose accessibility division has been collaborating with Synchron on Windows integration for BCI-driven input.

Clinicians involved in the trial have noted that patients are achieving meaningful communication speeds and reporting high satisfaction with the implant procedure and recovery time. One published case study from a Pittsburgh site described a patient with ALS who reached sustained typing rates comparable to smartphone use within six weeks of activation.

The broader industry is watching Synchron's regulatory trajectory closely, as a successful pivotal trial outcome would represent the first approved fully implanted BCI for motor restoration in the United States.